The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,123,714 | -8,168,927 | -1,823,351 | -214,239 |
| Forgiveness of unrelated vendor payables | - | 0 | 0 | 2,142,297 |
| Forgiveness of related party receivables | - | 126,275 | - | - |
| Depreciation | 518 | 543 | 542 | 743 |
| Change in fair value of deferred underwriting fee - paid in common stock | - | 0 | 560,000 | -756,000 |
| Change in the fair value of warrant liabilities | 4,178 | -94,335 | -76,871 | 116,894 |
| Loss on issuance of common stock in connection with the surrendar of warrants | - | 0 | -1,740,000 | - |
| Fair value of common stock to be issued for contingent liability | - | 7,360,000 | - | - |
| Due from related party, current | - | 0 | 0 | 3,427,000 |
| Prepaid and other current assets | 707,953 | -315,949 | 34,782 | -43,442 |
| Accounts payable and accrued expenses | -191,956 | 23,064 | -2,014,999 | -2,043,405 |
| Accrued interest, related parties | -18,637 | -19,051 | -19,052 | -177,800 |
| Accrued maintenance fee | - | - | - | 360,000 |
| Due to research and development partner | - | - | - | 1,782,297 |
| Due to related parties | -14,999 | 31,533 | 7,500 | -101,500 |
| Net cash used in operating activities | -2,015,289 | -386,847 | -600,612 | -8,975,859 |
| Loans to iris acquisition corp | - | 0 | 0 | 775,000 |
| Purchases of property and equipment | - | 0 | 13,108 | - |
| Net cash used in investing activities | - | 0 | -13,108 | -775,000 |
| Proceeds from issuance of common stock, net | 3,585,308 | 0 | 0 | 10,556,500 |
| Payment of transaction costs | - | 0 | 0 | 2,563,738 |
| Proceeds from issuance of short-term debt, related party | - | 0 | 0 | 4,340,000 |
| Repayment of short-term debt, related party | - | 0 | 0 | 1,300,000 |
| Net cash provided by financing activities | 3,585,308 | 0 | 0 | 11,032,762 |
| Net change in cash | 1,570,019 | -386,847 | -613,720 | 1,281,903 |
| Cash, beginning of the period | 337,655 | 724,502 | 1,338,222 | 56,319 |
| Cash, end of the period | 1,907,674 | 337,655 | 724,502 | 1,338,222 |
Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc. (LIMN)